Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3352589 in Healthy Volunteers
NCT03154086Phase 1Completed
- Sponsor
- GSK
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BOS-589 in irritable bowel syndrome (IBS) (11 arms), sponsored by GSK. Primary endpoints: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs up to 64 days, Number of Participants With Abnormal Findings After Physical Examination up to 64 days and 15 more. Started May 2017; status: completed.
02
Drugs
BOS-589
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT03154086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154086.